CTSOHIGH SIGNALFINANCIAL10-K

CTSO achieved dramatic 292% revenue growth while significantly reducing losses and improving cash position, though stockholders equity declined substantially.

The massive revenue acceleration from $5.7M to $22.5M alongside meaningful loss reduction suggests the company may be reaching an inflection point in commercialization of its medical devices. However, the 47% decline in stockholders equity raises questions about dilution or other capital structure changes that investors need to understand.

Comparing 2026-03-30 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

CTSO delivered exceptional top-line growth with revenue surging 292% to $22.5M while dramatically improving profitability metrics - net losses narrowed 60% and operating losses improved 12%. The company strengthened its balance sheet with cash nearly doubling to $6.2M and inventory increasing 93% to support growth, though stockholders equity fell significantly by 47%. Overall, the financial picture suggests a company successfully scaling its operations and moving toward profitability, but the equity decline warrants close scrutiny of the underlying capital structure changes.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+291.9%
$5.7M$22.5M

Strong top-line growth of 291.9% — accelerating demand or successful expansion into new markets.

Inventory
Balance Sheet
+93.2%
$2.7M$5.3M

Inventory surged 93.2% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Cash & Equivalents
Balance Sheet
+90.5%
$3.3M$6.2M

Cash position surged 90.5% — strong cash generation or capital raise providing significant financial cushion.

Net Income
P&L
+60.4%
-$20.7M-$8.2M

Net income grew 60.4% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
-46.9%
$11.1M$5.9M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
-42.3%
$284K$164K

Capex reduced 42.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+14.2%
-$14.4M-$12.4M

Operating cash flow grew 14.2% — strong conversion of earnings to cash, healthy business fundamentals.

Operating Income
P&L
+12.1%
-$16.8M-$14.7M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-31
ADDED
As of March 20, 2026, there were approximately 62.7 million outstanding shares of the registrant s common stock.
CytoSorbents lead product, CytoSorb , is approved in the European Union and distributed in more than 70 countries worldwide, with more than 300,000 devices used cumulatively to date.
CytoSorb is not yet approved, authorized, or cleared in the United States.
The Company is actively pursuing regulatory approval of DrugSorb-ATR with the FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA.
DrugSorb-ATR is not yet granted or approved in either the United States or Canada.
+7 more — sign up free →
REMOVED
As of March 31, 2025, there were approximately 62.5 million outstanding shares of the registrant s common stock.
This Annual Report contains our audited consolidated financial statements for the year ended December 31, 2024, and restates certain sections of the 2023 consolidated financial statements to correct misstatements related to inventory and stock-based compensation expense for restricted stock units.
Refer to Note 12 - Restatement of Previously Issued Financial Information, in the accompanying Consolidated Financial Statements included in Part II, Item 8 for additional information, including the impact on the specific financial statement line items.
Upon filing of this 2024 Annual Report, including the restated consolidated financial statements contained herein, the above referenced consolidated financial statements may be relied upon.
Impact on Internal Controls over Financial Reporting See Item 9A, Controls and Procedures, for information related to identified material weaknesses in internal control over financial reporting and the related remedial measures.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →